NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.
瑞士蘇黎世 /ACCESSWIRE /2023 年 10 月 19 日/ 專注於爲罕見和複雜中樞神經系統疾病患者發現和開發創新療法的瑞士臨床階段生物製藥公司NLS Pharmacetics Ltd.（納斯達克股票代碼：NLSP，NLSPW）（“NLS” 或 “公司”）今天宣佈，由於重要進展影響了活動時間，它將推遲原定於2023年10月20日星期五發布的公司更新。
About NLS Pharmaceutics Ltd.
關於 NLS 製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（納斯達克股票代碼：NLSP）是一家處於開發階段的全球生物製藥公司，與世界一流的合作伙伴和國際知名的科學家網絡合作，專注於爲醫療需求未得到滿足的罕見和複雜中樞神經系統疾病患者發現和開發創新療法。NLS總部位於瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，他們在開發和商業化候選產品方面有着良好的記錄。欲了解更多信息，請訪問。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
ml@nls-pharma.com
瑪麗安·蘭伯森（投資者和媒體）
NLS 製藥有限公司
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
來源： NLS 製藥股份公司
譯文內容由第三人軟體翻譯。